"infectious" optimism for treatment of hepatocellular carcinoma

Molecular Therapy

Volumn 21, Issue 4, 2013, Pages 722-724

  Tanabe, Kenneth K ^a   Chiocca, E Antonio ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC;

ADENOVIRUS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CYTOTOXICITY; DRUG MEGADOSE; HERPES VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; LOW DRUG DOSE; NOTE; RABIES VIRUS; TARGET CELL; VACCINIA VIRUS; VIRAL GENE THERAPY; VIRUS REPLICATION;

EID: 84878538343     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.47     Document Type: Note

References (10)

1. Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dose-fnding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med; e-pub ahead of print 10 February 2013.
2. Harrington, KJ et al. (2010). Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 16: 4005-4015.
3. Senzer, NN et al. (2009). Phase II clinical trial of a granu-locyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771.
4. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E and Forman, D (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90.
5. El-Serag, HB (2011). Hepatocellular carcinoma. N Engl J Med 365: 1118-1127.
6. Pack, GT (1950). Note on the experimental use of rabies vaccine for melanomatosis. AMA Arch Derm Syphilol 62: 694-695.
7. Chiocca, EA (2002). Oncolytic viruses. Nat Rev Cancer 2: 938-950.
8. Park, BH et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542.
9. Carmeliet, P and Jain, RK (2011). Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10: 417-427.
10. Villanueva, A and Llovet, JM (2011). Targeted therapies for hepatocellular carcinoma. Gastroenterology 140: 1410-1426.